Company DescriptionOur research focuses on developing new treatments for depression based on subtype-selective modulation of phosphodiesterase 4B (PDE4B). PDE4 in neurons is responsible for the hydrolysis of cAMP. We and our colleagues recently described the protein structure of a key PDE4 regulatory domain known as UCR2.

Proceeds PurposesWe are very pleased to receive this new financing which will enable Tetra to complete the necessary preparations for a planned Phase 2a study of our lead drug candidate, BPN14770, in Alzheimer’s disease during the second half of 2017.